Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Skyhawk raises $40mm through Series A round concurrent with Celgene deal

Executive Summary

Skyhawk Therapeutics Inc. (small-molecule drug discovery) raised $40mm through its Series A round from Alexandria Venture Investments, GreatPoint Ventures, Celgene, ShangPharma Innovation, Agent Capital, and major family investors including Tim Disney, the Duke of Bedford, the Reilly family, and other others.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies